News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Shannon Matheny

Articles by Shannon Matheny

29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Erika P. Hamilton, MD,Sara A. Hurvitz, MD,Sara M. Tolaney, MD, MPH,Virginia Kaklamani, MD, DSc,Paula Muñoz Romero,Shannon Matheny,Kathy Puyana Theall,Joyce A. O’Shaughnessy

July 21st 2024

Latest Updated Articles

Trending on CancerNetwork

Navigating CAR T-Cell Therapy Use as a “Team Sport” in Multiple Myeloma

Concomitant COVID-19 Vaccination Tied to Improved OS with Immunotherapy

FDA Approves Dato-DXd for Metastatic Triple-Negative Breast Cancer

FDA Approves FoundationOne CDx for Tepotinib in MET+ NSCLC

91 Real-World Survival Outcomes by Risk Features in Patients With HR+/HER2− Early Breast Cancer in the United States